These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 37002373)

  • 1. Incidence and trend of antiresorptive agent-related osteonecrosis of the jaw from 2016 to 2020 in Kure, Japan.
    Kunihara T; Tohmori H; Tsukamoto M; Kobayashi M; Okumura T; Teramoto H; Hamasaki T; Yamasaki T; Nakagawa T; Okimoto N; Fujiwara S
    Osteoporos Int; 2023 Jun; 34(6):1101-1109. PubMed ID: 37002373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiresorptive Agent-Related Osteonecrosis of the Jaw (ARONJ): A Twist of Fate in the Bone.
    Shibahara T
    Tohoku J Exp Med; 2019 Feb; 247(2):75-86. PubMed ID: 30713280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CT imaging features of antiresorptive agent-related osteonecrosis of the jaw/medication-related osteonecrosis of the jaw.
    Baba A; Goto TK; Ojiri H; Takagiwa M; Hiraga C; Okamura M; Hasegawa S; Okuyama Y; Ogino N; Yamauchi H; Kobashi Y; Yamazoe S; Munetomo Y; Mogami T; Nomura T
    Dentomaxillofac Radiol; 2018 May; 47(4):20170323. PubMed ID: 29365278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Osteonecrosis of the Jaw and Antiresorptive Agents in Benign and Malignant Diseases: A Critical Review Organized by the ECTS.
    Anastasilakis AD; Pepe J; Napoli N; Palermo A; Magopoulos C; Khan AA; Zillikens MC; Body JJ
    J Clin Endocrinol Metab; 2022 Apr; 107(5):1441-1460. PubMed ID: 34922381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence, Incidence Rate, and Risk Factors of Medication-Related Osteonecrosis of the Jaw in Patients With Osteoporosis and Cancer: A Nationwide Population-Based Study in Japan.
    Ishimaru M; Ono S; Morita K; Matsui H; Hagiwara Y; Yasunaga H
    J Oral Maxillofac Surg; 2022 Apr; 80(4):714-727. PubMed ID: 35033505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Frequency of Medication-related Osteonecrosis of the Jaw and its Associated Risk Factors.
    Dodson TB
    Oral Maxillofac Surg Clin North Am; 2015 Nov; 27(4):509-16. PubMed ID: 26362367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging therapies with potential risks of medicine-related osteonecrosis of the jaw: a review of the literature.
    Kanwar N; Bakr MM; Meer M; Siddiqi A
    Br Dent J; 2020 Jun; 228(11):886-892. PubMed ID: 32541753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug-induced osteonecrosis of the jaw: the state of the art.
    Fassio A; Bertoldo F; Idolazzi L; Viapiana O; Rossini M; Gatti D
    Reumatismo; 2017 May; 69(1):9-15. PubMed ID: 28535616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of Osteonecrosis of the Jaw Under Denosumab Compared to Bisphosphonates in Patients With Osteoporosis.
    Everts-Graber J; Lehmann D; Burkard JP; Schaller B; Gahl B; Häuselmann H; Studer U; Ziswiler HR; Reichenbach S; Lehmann T
    J Bone Miner Res; 2022 Feb; 37(2):340-348. PubMed ID: 34787342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cooperation between physicians and dentists for osteonecrosis of the jaw: a 2022 Japanese survey.
    Taguchi A; Hagino H; Inoue D; Endo N; Society JO
    J Bone Miner Metab; 2023 Nov; 41(6):829-837. PubMed ID: 37516668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medication-related osteonecrosis of the jaw: risk factors in patients under biphosphonate versus patients under antiresorptive-antiangiogenic drugs.
    Ghidini G; Manfredi M; Giovannacci I; Mergoni G; Sarraj A; Mureddu M; Giunta G; Bonanini M; Meleti M; Vescovi P
    Minerva Stomatol; 2017 Aug; 66(4):135-140. PubMed ID: 28497661
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medication-related osteonecrosis of the jaw: An update on the memorial sloan kettering cancer center experience and the role of premedication dental evaluation in prevention.
    Owosho AA; Liang STY; Sax AZ; Wu K; Yom SK; Huryn JM; Estilo CL
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2018 May; 125(5):440-445. PubMed ID: 29580668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bisphosphonate-associated osteonecrosis of the jaw in Ontario: a survey of oral and maxillofacial surgeons.
    Khan AA; Rios LP; Sándor GK; Khan N; Peters E; Rahman MO; Clokie CM; Dore E; Dubois S
    J Rheumatol; 2011 Jul; 38(7):1396-402. PubMed ID: 21498483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A systematic review of metastatic cancer presenting in osteonecrosis of the jaws (MC-ONJ) in patients undergoing antiresorptive and/or antiangiogenic therapy for skeletal-related adverse events.
    Sacco R; Woolley J; Yates J; Calasans-Maia MD; Akintola O; Patel V
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2021 Jun; 131(6):650-659. PubMed ID: 33518491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Current situation and future issues of antiresorptive agent-related osteonecrosis of the jaw].
    Takaoka K; Kishimoto H
    Nihon Yakurigaku Zasshi; 2019; 153(1):22-27. PubMed ID: 30643088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Osteonecrosis of the jaws: a 14-year retrospective survey of hospital admissions.
    McGowan K; Ivanovski S; Acton C
    Aust Dent J; 2018 Jun; 63(2):202-207. PubMed ID: 29432652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is the prevalence of the medication-related osteonecrosis of the jaws underestimated, evaluation in oncological and non-oncological disease.
    Galis B; Zajko J; Hirjak D; Vanko L; Kupcova I; Jurkemik J; Gengelova P; Mikuskova K; Halmova K; Riznic M; Czako L
    Bratisl Lek Listy; 2017; 118(12):724-731. PubMed ID: 29322803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osteonecrosis of the Jaw in Patients Receiving Bone-Targeted Therapies: An Overview--Part I.
    Turner B; Drudge-Coates L; Ali S; Pati J; Nargund V; Ali E; Cheng L; Wells P
    Urol Nurs; 2016; 36(3):111-6, 154. PubMed ID: 27501591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Osteonecrosis of jaw beyond antiresorptive (bone-targeted) agents: new horizons in oncology.
    Fusco V; Santini D; Armento G; Tonini G; Campisi G
    Expert Opin Drug Saf; 2016 Jul; 15(7):925-35. PubMed ID: 27074901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical considerations for medication-related osteonecrosis of the jaw: a comprehensive literature review.
    Kawahara M; Kuroshima S; Sawase T
    Int J Implant Dent; 2021 May; 7(1):47. PubMed ID: 33987769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.